
Moderna (NSDQ:MRNA) announced today that it received full FDA approval of the biologics license application for its COVID-19 vaccine.
FDA’s approval for the company’s Spikevax mRNA COVID-19 vaccine covers the prevention of the virus in individuals aged 18 years or older. Moderna submitted for full FDA approval back in June 2021 and becomes the second fully FDA-approved COVID-19 vaccine after the Pfizer-BioNTech vaccine received approval in August 2021.
Get the full story at our sister site, Pharmaceutical Processing World.